Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation

References

• Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-contain-ing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–4536.
   PubMed Web of Science ®Google Scholar
• Khouri I, Keating M, Korbling M. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonabla-tive chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817–2824.
   Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cyto-reduction for the treatment of malignant and non-malignant hematologic disease. Blood 1998;91:756–763.
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26:119–124.
   PubMed Web of Science ®Google Scholar
• Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102:470–476.
   PubMed Web of Science ®Google Scholar
• Mineishi S, Kanda Y, Saito T, et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003;121:296–303.
   PubMed Web of Science ®Google Scholar
• Levine JE, Uberti JP, Ayash L, et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003;9:189–197.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hemato-poietic stem cell transplantation. Blood 2003;102:756–762.
   PubMed Web of Science ®Google Scholar
• Nakai K, Mineishi S, Kami M, et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune recon-stitution. Transplantation 2003;75:21–35.
   Web of Science ®Google Scholar
• Schulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathological study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Sullivan Km. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic cell transplantation. Cambridge, MA: Blackwell Scientific Publications; 1999. p 515–536.
   Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003;9:215–233.
   PubMed Web of Science ®Google Scholar
• Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow transplantation: A comparison of patient report with population norms. Bone Marrow Transplant 1997;19:1129–1136.
   PubMed Web of Science ®Google Scholar
• Duell T, Van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation: EBMT Working Party on late effects and EULEP Study Group on late effects: European group for blood and marrow transplantation. Ann Intern Med 1997;126:184–192.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989;74:1428–1435.
   PubMed Web of Science ®Google Scholar
• Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14–21.
   PubMed Web of Science ®Google Scholar
• Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002;100:415–419.
   PubMed Web of Science ®Google Scholar
• Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. Biol Blood and Marrow Transplant 2003;9:52–59.
   PubMed Web of Science ®Google Scholar
• Cutler C, Gin i S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Chin Oncol 2001;19:3685–3691.
   PubMed Web of Science ®Google Scholar
• Nash RA, Johnston L, Parker PM, et al. A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclo-sporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF. Blood 2003;102:240a.
   Web of Science ®Google Scholar
• Bolwell BJ, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine + short course methotrexate to cyclosporine + mycophenolate for GVHD prophylaxis in ablative allogeneic BMT. Blood 2003;102:711a.
   Web of Science ®Google Scholar
• Colson YL, Lange J, Fowler K, Lidstad ST. Mechanism for cotolerance in nonlethally conditioned mixed chimeras: Negative selection of the V13 T-cell receptor repertoire by both host and donor bone marrow-derived cells. Blood 1996;88:4601–4610.
   PubMed Web of Science ®Google Scholar
• Ordemann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Chin Invest 2002;109:1249–1256.
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: The role of grastrointest-inal damage and inflammatory cytokines. Blood 1997;90:3204–3213.
   PubMed Web of Science ®Google Scholar
• Hill GR, Teshima T, Gerbita A, et al. Differential roles of IL-1 and TNF-ek on graft-versus-host disease and graft-versus leukaemia. J Chin Invest 1999;104:459–462.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575–581.
   PubMed Web of Science ®Google Scholar
• Chan GW, Gorgun G, Miller KB, et al. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood and Marrow Transplant 2003;9:170–176.
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood and Marrow Transplant 2004;10:178–185.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2002;96:2419–2425.
   Web of Science ®Google Scholar
• Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004;33:691–696.
   PubMed Web of Science ®Google Scholar